The Clinical Analysis Of Elderly Patients With Advanced Non-small Cell Lung Cancer

Background and Objectives:Incidence of lung cancer have been increasing in developed countries and highestin the large and medium cities in China have lived in cancer mortality, and are at highrisk of lung cancer in the elderly population. To date treatment of elderly patients withadvanced non-small cell lung cancer, there is no standard programme, this studyprovides an analysis on the choice of elderly patients with advanced non-small cell lungcancer treatment options to get greater survival benefit and well tolerated andreasonable choice of guided clinical rationale provided individualized treatmentprogrammes.Method:In this study, from January1,2008to December31,2011, the Liaoning ProvincialTumor Hospital medical word were treated232admitted cases of elderly patients withadvanced non-small cell lung cancer were retrospectively analyzed clinical data,treatment is divided into four groups: single-agent chemotherapy, platinum-containingtwo-drug combination chemotherapy, non-platinum drug combination chemotherapyand best supportive care group. The application SPSS21statistical software tocompare the short-term effect of these four groups of treatment programs,long-term efficacy and adverse reactions, each group efficiency, disease controlrate and adverse reaction rate using the chi-square test, survival analysis wasperformed using the Kaplan-Meier method, the survival curve hypothesis testingusing the Log-rank method. Results:The short-term efficacy: The single-agent chemotherapy response rate was20%,two-drug combination platinum-containing chemotherapy group was41.4%, the resultof the comparison of these two sets of efficient chi-square value of4.900,1degree offreedom, the difference was statistically significance (P <0.05). Single-agentchemotherapy group the disease control rate was56.7%, the two-drug combinationchemotherapy with platinum disease control rate was72.8%, the result of thecomparison of these two sets of disease control rate chi-square value of3.172,1degreeof freedom, the difference was not statistically significant (P>0.05).Adverse reactions: all adverse reactions, gastrointestinal reactions and theincidence of hematologic toxicity, liver toxicity, kidney toxicity, cardiac toxicity,allergic reactions and rashes; only I-II degree of bloodtoxicities and the incidence ofgastrointestinal reactions of four groups than the difference was statistically significant(P <0.05), and other aspects of adverse reactions between the four groups the differencewas not statistically significant (P>0.05).The long-term efficacy: As of the last follow-up,232patients,50cases were lost tofollow-up,110deaths,72patients survived. These three groups of single-agentchemotherapy, including platinum two-drug combination chemotherapy, best supportivecare group, the median survival time of9.5months,12months,8months;1-yearsurvival rates were36.9%,51.4%,27%;2-year survival for single-agent chemotherapygroup9.2%, platinum-containing two-drug combination chemotherapy group13.3%;survival of three groups: the chi-square value of5.474, degrees of freedom2, P value0.065, the difference was not significant (P>0.05）。Conclusion:1. The treatment of elderly patients with advanced non-small cell lung cancerPlatinum two drug combined with chemotherapy compared with high efficiency ofsingle-agent chemotherapy, therapeutic good.2. Rated in good condition elderly patients with advanced non-small cell lungcancer patients able to tolerate the side effects caused by chemotherapy. Containingplatinum group of hematologic toxicity I-II degree and gastrointestinal reactions washigher than in the other groups, the symptomatic treatment recoverable; adversereactions of the other aspects of the group differences.3. The overall survival time of each group difference was not statisticallysignificant, solely from the point of view of survival curves, chemotherapy is superior to best supportive care group, platinum-containing two-drug combination group wassuperior to monotherapy group.